MICA is expressed on epithelial cells, especially of the gastrointestinal (GI) tract, fibroblasts, endothelial cells, monocytes and dendritic cells. MICA binds the activating NKG2D receptor on natural killer (NK) cells and certain T-cells to induce cytolytic activity and/or cytokine production. Immune responses in solid organ transplant recipients are mounted against different protein forms of MICA alleles. Antibodies can be generated by mismatched amino acids in transplant recipients and have been found against MICA in organ transplants that are rejected. Presence of MICA antibodies is associated with decreased kidney transplant survival and also seen for heart transplants. MICA mismatching in hematopoietic cell transplantation has been associated with increased risk of graft-versus-host disease (GVHD), with allogeneic transplanted T-cells or NK cells targeting mismatched MICA proteins in the GI tract of the transplant recipient.
For transplant recipients, donors are matched for most HLA antigens to reduce GVHD. Most of the genes that code for HLA antigens are located in the same region of the genome, known as the MHC region. MICA is located in this region, located 46 kilobases centromeric to HLA-B, an HLA antigen used to match donor and recipients. Because of the close proximity, MICA alleles are linked to inheritance of HLA-B alleles. By mapping the MHC region for all polymorphisms, recipients and donors can be matched better to reduce the risks of GVHD or graft rejection in transplant recipients.
Previously, MICA alleles have been genotyped through sequence-specific primers, sequence-specific oligonucleotide probes, or direct sequencing of the gene to identify nucleotide changes. Typing of the transmembrane region (exon 5) of MICA has commonly been performed by PCR and sizing of the amplified fragments that consist of variable numbers of GCT nucleotide repeats. Research technician Dawn Morgan and colleagues in the Pettersdorf lab developed a new method to co-amplify and sequence both alleles of MICA across exons 1-5 and to physically link polymorphisms across the exons using haplotype-specific extraction (HSE) to separate diploid genomic DNA into its haploid components. Using this method, 52 known polymorphisms in exons 2, 3, and 4 can be genotyped for polymorphic allele combinations with the exception of 16 alleles that have identical sequences in exons 2, 3, and 4. 595 of 1217 ambiguous allele combinations can further be identified by sequencing exon 5 in the reverse direction to examine the four polymorphic positions and the GCT short tandem repeat in this exon.
By using this method, the researchers identified the novel MICA*070 allele in an individual with Caucasian background. This allele was similar to sequences of alleles MICA*008:01 and/or MICA*008:04 in exons 2, 3, 4, and 5. Two oligonucleotide probes were designed to separate the MICA*008 allele in exon 1 and MICA*070 allele in exon 2 using HSE and determine the linkage of the two alleles, whether they occur on the same DNA strand of the chromosome. This phasing showed that the MICA*070 allele is a variant of the MICA*008:04 allele, with the additional substitution of G to C in nucleotide position 183 in exon 2. This results in a non-synonymous amino acid change of arginine to serine at residue 38 of the α1 domain. This novel allele increases the diversity of the MICA genetic locus, and suggests that complete characterization of exons 1-5 is required to type the majority of the MICA polymorphisms.
A homodimer of NKG2D receptors binds the α1 and α2 domains of MICA (see figure), as determined by structural analysis in the laboratory of Dr. Roland Strong in the Basic Sciences Division (Li et al., 2001). Since the amino acid substitution of serine at residue 38 instead of arginine is within the region of NKG2D binding, future studies are needed to determine the significance of this amino acid change in MICA and NKG2D interactions. Disruption or weakening of MICA interaction with NKG2D may alter the activation of NK cells or the modulation of T-cells (Steinle et al., 2001).
Moran D., Morishima S., Malkki M., and Petersdorf E.W. 2012. Identification of the MICA(∗)070 allele by sequencing and phasing. Human Immunololgy. Epub ahead of print, doi: 10.1016/j.humimm.2012.11.009.
Also see: Zou Y. and Stastny P. 2010. Role of MICA in the immune response to transplants. Tissue Antigens. 76:171-6.
Li P., Morris D.L., Willcox B.E., Steinle A., Spies T., and Strong R.K. 2001. Complex structure of the activating immunoreceptor NKG2D and its MHC class I-like ligand MICA. Nature Immunology. 5:443-51.
Steinle A., Li P., Morris D.L., Groh V., Lanier L.L., Strong R.K., and Spies T. 2001. Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family. Immunogenetics. 53:279-8